Merck Research and Development Expenses 2012-2026 | MRK
Merck annual/quarterly research and development expenses history and growth rate from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Merck research and development expenses for the quarter ending March 31, 2026 were $12.592B, a 247.75% increase year-over-year.
- Merck research and development expenses for the twelve months ending March 31, 2026 were $24.760B, a 40.95% increase year-over-year.
- Merck annual research and development expenses for 2025 were $15.789B, a 11.98% decline from 2024.
- Merck annual research and development expenses for 2024 were $17.938B, a 41.25% decline from 2023.
- Merck annual research and development expenses for 2023 were $30.531B, a 125.35% increase from 2022.
|
Merck Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $15,789 |
| 2024 | $17,938 |
| 2023 | $30,531 |
| 2022 | $13,548 |
| 2021 | $12,245 |
| 2020 | $13,397 |
| 2019 | $9,724 |
| 2018 | $9,752 |
| 2017 | $10,339 |
| 2016 | $10,261 |
| 2015 | $6,704 |
| 2014 | $7,180 |
| 2013 | $7,503 |
| 2012 | $8,168 |
| 2011 | $8,467 |
|
Merck Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $12,592 |
| 2025-12-31 | $3,886 |
| 2025-09-30 | $4,234 |
| 2025-06-30 | $4,048 |
| 2025-03-31 | $3,621 |
| 2024-12-31 | $4,584 |
| 2024-09-30 | $5,862 |
| 2024-06-30 | $3,500 |
| 2024-03-31 | $3,992 |
| 2023-12-31 | $9,627 |
| 2023-09-30 | $3,307 |
| 2023-06-30 | $13,321 |
| 2023-03-31 | $4,276 |
| 2022-12-31 | $3,775 |
| 2022-09-30 | $4,399 |
| 2022-06-30 | $2,798 |
| 2022-03-31 | $2,576 |
| 2021-12-31 | $3,067 |
| 2021-09-30 | $2,445 |
| 2021-06-30 | $4,321 |
| 2021-03-31 | $2,412 |
| 2020-12-31 | $5,754 |
| 2020-09-30 | $3,349 |
| 2020-06-30 | $2,085 |
| 2020-03-31 | $2,209 |
| 2019-12-31 | $2,400 |
| 2019-09-30 | $3,204 |
| 2019-06-30 | $2,189 |
| 2019-03-31 | $1,931 |
| 2018-12-31 | $2,214 |
| 2018-09-30 | $2,068 |
| 2018-06-30 | $2,274 |
| 2018-03-31 | $3,196 |
| 2017-12-31 | $2,314 |
| 2017-09-30 | $4,413 |
| 2017-06-30 | $1,782 |
| 2017-03-31 | $1,830 |
| 2016-12-31 | $4,787 |
| 2016-09-30 | $1,664 |
| 2016-06-30 | $2,151 |
| 2016-03-31 | $1,659 |
| 2015-12-31 | $1,797 |
| 2015-09-30 | $1,500 |
| 2015-06-30 | $1,670 |
| 2015-03-31 | $1,737 |
| 2014-12-31 | $2,283 |
| 2014-09-30 | $1,659 |
| 2014-06-30 | $1,664 |
| 2014-03-31 | $1,574 |
| 2013-12-31 | $1,835 |
| 2013-09-30 | $1,660 |
| 2013-06-30 | $2,101 |
| 2013-03-31 | $1,907 |
| 2012-12-31 | $2,223 |
| 2012-09-30 | $1,918 |
| 2012-06-30 | $2,165 |
| 2012-03-31 | $1,862 |
| 2011-12-31 | $2,419 |
| 2011-09-30 | $1,954 |
| 2011-06-30 | $1,936 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |